2420563-99-9

2420563-99-9 structure

Name: Cilgavimab
Chemical Name: Cilgavimab
CAS Number: 2420563-99-9
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2023-01-17 07:47:02
Modify Date: 2024-01-29 18:17:56
Cilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection[1].

Name	Cilgavimab

Description	Cilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV
Target	SARS-CoV-2[1][2]
In Vitro	Cilgavimab 和 Tixagevimab 能够同时结合到 SARS-CoV-2 刺突蛋白 (S) 受体结合域的不同、不重叠的表位，以有效中和病毒[1]。 Cilgavimab 具有较强的单克隆抗体中和活性和人 ACE2 阻断活性，IC50 为 10-150 ng/mL，并能与三聚体 S2Pecto 蛋白或单体 SRBD 蛋白结合，IC50 为 0.1-10 ng/mL[2]。
In Vivo	Cilgavimab (200 μg/小鼠; 腹腔注射; 感染 SARS-CoV-2 前 1 h 处理) 保护小鼠免于体重减轻，减少病毒负担和肺部炎症水平[2]。
References	[1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200. [2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449.

No Any Chemical & Physical Properties